SISAQOL-IMI is good news for patients taking part in cancer clinical trials as their experiences will be better captured, alongside valuable information on treatment risks, benefits and tolerability of treatments. This project and its generated recommendations is also of importance to organisations like the European Medicines Agency (EMA) and the Food and Drug Administration (FDA), as PRO data presented in the same way across trials and cancers will help support fair and informed decision making.
This in turn may lead to improved patient satisfaction with medicines and treatments, an increased likelihood of adherence to treatment, higher likelihood of treatment success, and a reduction in health‐care cost in the long term. Patients have been involved in the project from the very beginning, and through WECAN, will continue to be involved.
Patients are responsible for communication and dissemination of all project findings and ensuring that any messages emerging from the project are published in plain language so they can be read and understood by all. Findings will also be translated into different European languages.
Please use the ‘contact us’ button to find out more!